In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates

BACKGROUND AND OBJECTIVES TNP-2092 is a novel dual-action lead compound consisting of rifamycin SV and 4H-4-oxo-quinolizine pharmacophores, with a broad spectrum of antibacterial activities. This compound is currently in the early stage of clinical development for Helicobacter pylori inf...

詳細記述

書誌詳細

主要な著者:	Ben Wang, Qiaoyun Zhao, Wenzhu Yin, Ying Yuan, Xiaomei Wang, You-hua Wang, Hui Wang, Wen Ye, Shuping Chen, Hai-long Guo, Yong Xie
フォーマット:	Artigo
言語:	Inglês
出版事項:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2018-07-01
シリーズ:	Swiss Medical Weekly
主題:	Helicobacter pylori drug resistant
オンライン･アクセス:	https://www.smw.ch/index.php/smw/article/view/2501
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!